Target intelligence / Profile preview

Diphtheria Toxin Mutant (CRM197) (CRM197)

Target
CRM197
Molecular classification
Toxin (mutated), Enzyme (inactive ADP-ribosyltransferase)
01

Overview

CRM197 is a well-characterized non-toxic mutant form of diphtheria toxin that serves primarily as an effective carrier protein in modern conjugate vaccines targeting encapsulated bacteria. Its unique single-point mutation (G52E) renders it safe while maintaining strong immunostimulatory properties essential for pediatric vaccination programs worldwide. Ongoing research explores additional therapeutic uses based on its ability to interact with cellular receptors beyond classical vaccine roles, particularly its potential as an inhibitor of HB-EGF signaling in cancer.

Other names
Corynebacterium diphtheriae CRM197 protein
02

Mechanism of action

Conjugation to polysaccharides to elicit T-cell dependent immune responses; Inhibition of HB-EGF-mediated signaling (potential)

03

Biological functions

Vaccine carrier proteinImmune response enhancementHeparin-binding EGF-like growth factor (HB-EGF) inhibitor (potential)Mitogenic activity inhibitor (potential)
04

Disease associations

Infection (prevention via vaccination)Cancer (potential therapeutic target via HB-EGF inhibition)
05

Safety considerations

Potential toxicity in certain cell lines at high concentrationsCarrier-induced suppression (potential, less than other carriers)

Beyond the preview

Go deeper on Diphtheria Toxin Mutant (CRM197) (CRM197).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diphtheria Toxin Mutant (CRM197) (CRM197).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call